FGK Representative Service
FGK Representative Service is recorded as a service provider in 7 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 7 of 7 trials · Latest update first
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Oral PIPE-791 in Subjects with Idiopathic Pulmonary Fibrosis
Sponsor Contineum Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Efficacy and Safety of surlorian (ARM210, S48168) in Adults with Autosomal Dominant RYR1-Related Myopathy
Sponsor Rycarma Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3b Multicenter Open-label Trial of the Safety, Tolerability, and Efficacy of Tolvaptan in Infants and Children 28 days to less than 18 years of Age with Autosomal Recessive Polycystic Kidney Disease (ARPKD).
Sponsor Otsuka Pharmaceutical Development & Commercialization Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2 Proof of Concept Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of OMS906 in Patients with C3 Glomerulopathy (C3G) and Idiopathic Immune Complex-Mediated Glomerulonephritis (ICGN)
Sponsor Omeros Corp.
- Start (EU)
- Latest update
- Estimated end
A Phase 3 Randomized, Open Label Study to Evaluate the Efficacy and Safety of Tobevibart+Elebsiran Combination Therapy in Participants with Chronic HDV Infection Not Virologically Suppressed with Bulevirtide (ECLIPSE 2)
Sponsor Vir Biotechnology Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3b Multicenter Open-label Trial of the Safety, Tolerability, and Efficacy of Tolvaptan in Infants and Children 28 days to less than 12 weeks of Age with Autosomal Recessive Polycystic Kidney Disease (ARPKD).
Sponsor Otsuka Pharmaceutical Development & Commercialization Inc.
- Start (EU)
- Not reported
- Latest update
- Estimated end
A Phase 3 Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Tobevibart+Elebsiran Combination Therapy in Participants with Chronic HDV Infection (ECLIPSE 1)
Sponsor Vir Biotechnology Inc.
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for FGK Representative Service?
The 2026-10-09 snapshot links FGK Representative Service to 7 distinct CTIS trials. Recorded services include EU legal representative, EU Legal Representative, EU legal Representative for Sponsor, Legal Representation, among 5 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for FGK Representative Service?
The most frequently recorded therapeutic areas are Genetic and Congenital Disorders, Musculoskeletal, Neurology, Respiratory. Recorded phases include Phase 2. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to FGK Representative Service conducted?
The linked trials record locations in 13 countries, including Germany, Spain, France, Poland, Belgium. These are trial locations, not confirmed office locations or countries where FGK Representative Service delivered services.
What can this page tell me about FGK Representative Service's trial experience?
Browse 7 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under FGK Representative Service. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- FGK Representative Service B.V.